Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial
نویسندگان
چکیده
ISSN 2041-6792 10.4155/CLI.10.5 © 2011 Future Science Ltd Amplification of the HER2 gene and/or overexpression of its encoded protein have been observed in a proportion of patients with advanced gastric cancer (AGC). Activity of trastuzumab, a humanized monoclonal antibody against HER2, has been investigated in preclinical AGC models, anecdotal case reports and a few pilot trials. More recently, the Phase III Trastuzumab for Gastric Cancer (ToGA) trial found that trastuzumab treatment improved overall survival in AGC patients with amplification or overexpression of HER2. This article will describe the results of the ToGA trial, its impact on treatment of patients with AGC and the implications of these findings.
منابع مشابه
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
PURPOSE While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. MATERIALS AND METHODS Data of pat...
متن کاملUpdates in HER2 Testing in Gastric Cancer
Gastric adenocarcinoma is a major cause of morbidity and mortality in the world with median overall survival being less than a year [1-4]. Advanced gastric adenocarcinoma is associated with a dismal prognosis, and increasing survival time, even by a few months, can be significant in this patient population [3,5,6]. Recently there was a major breakthrough in the treatment of gastric cancer, whic...
متن کاملGastric cancer: trastuzumab trial results spur search for other targets.
I mproving outcomes for advanced gastric cancer patients has been frustratingly difficult to achieve. Despite many trials, no chemotherapy regimen has provided a median survival beyond 1 year. That’s why many were stunned when results from the fi rst randomized prospective phase III trial testing trastuzumab (Herceptin) in gastric cancer showed overall survival of 13.8 months in the treatment g...
متن کاملEpidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Esophageal and gastric cancer incidence has been increasing worldwide. Most cases are diagnosed in advanced stages, and current therapy has not been able to improve the modest survival rates after diagnosis. Epidermal growth factor receptor expression has been found to correlate with poor prognosis and aggressive disease in esophagogastric cancers. Targeting these receptors through monoclonal a...
متن کاملTargeting the human epidermal growth factor receptor 2 in esophageal cancer.
The importance of human epidermal growth factor-2 (HER2) in terms of prognosis and aggressiveness of growth has long been known in breast cancer, and interruption of its growth cascade by agents such as trastuzumab and lapatinib has markedly improved outcomes for these patients with HER2 overexpression. HER2 overexpression also occurs in many other tumor types, including esophageal cancer. In t...
متن کامل